Influencing factors for dynamic changes in the severity of fatty liver in patients with acute pancreatitis and fatty liver

Qiang CHEN; Mingkuan JIANG; Miao ZHANG; Lin LUO; Lirong ZHANG

doi:10.3969/j.issn.1001-5256.2023.06.018

Volume 39 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(6): 1374-1381

PDF( 1811 KB)

Influencing factors for dynamic changes in the severity of fatty liver in patients with acute pancreatitis and fatty liver

DOI: 10.3969/j.issn.1001-5256.2023.06.018

1.
Department of Medical Imaging, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia Autonomous Region 014010, China
2.
Department of Radiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Research funding:

Seedling Project of Baotou Medical College (BYJJ-QM-201753)

More Information

Corresponding author: ZHANG Lirong, yfyz_1466@163.com (ORCID: 0000-0002-6295-0605)
Received Date: 2022-10-23
Accepted Date: 2022-11-29
Published Date: 2023-06-20

Abstract

Abstract

Objective To investigate the dynamic change of fatty liver (FL) in patients with fatty liver-related acute pancreatitis (FLAP) and related influencing factors. Methods A total of 136 FLAP patients who were admitted to The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, from December 2017 to December 2021 were enrolled as subjects. With the first CT examination after admission as the starting point and the last CT examination before discharge as the ending point, the subjects were divided into FL aggravation group (FLAG group), FL mild mitigation group (FLMMG group), and FL significant mitigation group (FLSMG group) according to the degree of change in FL. General information and clinical data were compared between groups. General information included age, sex, length of hospital stay, etiology of acute pancreatitis (AP), and changes in body weight and temperature, and clinical data included treatment modality and the changes in laboratory markers and AP severity. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups, and the Mann-Whitney U test with Bonferroni correction was used for further comparison between two groups. Dynamic changes of data were expressed as the difference from the starting point to the ending point, and a covariance analysis was used for comparison of data with dynamic changes. The Spearman correlation analysis was used to investigate the correlation of indices with significant changes with the degree of change in FL. Results Among the 136 FLAP patients, 61 achieved mild mitigation of FL, 59 achieved significant mitigation of FL, and 16 experienced aggravation of FL at the ending point of the study. There were significant differences between the three groups in the length of hospital stay (χ²=16.215, P < 0.001) and the change in body weight (F=3.908, P < 0.05), and the FLSMG group had a greater reduction in body weight and a longer length of hospital stay. There were also significant differences between the three groups in the number of fasting days (χ²=11.020, P=0.004) and the degree of changes in C-reactive protein (CRP) (F=8.589, P < 0.001), white blood cell count (WBC) (F=5.448, P=0.005), and CT severity index (CTSI) (F=7.544, P=0.001), and the FLSMG group had greater reductions in CRP, WBC, and CTSI and a longer duration of fasting. Length of hospital stay, number of fasting days, and changes in CRP and CTSI were significantly correlated with the change in FL (r=0.352, 0.372, -0.365, and -0.350, all P < 0.001). Conclusion Most FLAP patients tend to have mitigation of FL, and its dynamic changes are closely associated with the changes in CRP and CTSI.
- Pancreatitis,
- Fatty Liver,
- Body Weight,
- C-Reactive Protein,
- CT Severity Index

FullText(HTML)

References(25)

References

[1]	LI CL, JIANG M, PAN CQ, et al. The global, regional, and national burden of acute pancreatitis in 204 countries and territories, 1990-2019[J]. BMC Gastroenterol, 2021, 21(1): 332. DOI: 10.1186/s12876-021-01906-2.
[2]	WU D, ZHANG M, XU S, et al. Nonalcoholic fatty liver disease aggravated the severity of acute pancreatitis in patients[J]. Biomed Res Int, 2019, 2019: 9583790. DOI: 10.1155/2019/9583790.
[3]	SONG Y, ZHANG P, XU SW, et al. Predictive value of CT evaluation of fatty liver for the severity of acute pancreatitis[J]. Chin J Postgrad Med, 2018, 41(8): 701-705. DOI: 10.3760/cma.j.issn.1673-4904.2018.08.008. 宋宇, 张鹏, 许尚文, 等. CT评估脂肪肝对急性胰腺炎严重程度的预测价值[J]. 中国医师进修杂志, 2018, 41(8): 701-705. DOI: 10.3760/cma.j.issn.1673-4904.2018.08.008.
[4]	MIKOLASEVIC I, ORLIC L, POROPAT G, et al. Nonalcoholic fatty liver and the severity of acute pancreatitis[J]. Eur J Intern Med, 2017, 38: 73-78. DOI: 10.1016/j.ejim.2016.10.019.
[5]	YOON SB, LEE IS, CHOI MH, et al. Impact of fatty liver on acute pancreatitis severity[J]. Gastroenterol Res Pract, 2017, 2017: 4532320. DOI: 10.1155/2017/4532320.
[6]	JIANG MK, ZHANG M, ZHANG LR, et al. Impact of fatty liver on acute pancreatitis severity and prognosis: A meta-analysis of English and Chinese studies[J]. Radiol Infect Dis, 2021, 8(4): 140-149. DOI: 10.4103/RID.RID_10_22.
[7]	VÁNCSA S, NÉMETH D, HEGYI P, et al. Fatty liver disease and non-alcoholic fatty liver disease worsen the outcome in acute pancreatitis: A systematic review and Meta-analysis[J]. J Clin Med, 2020, 9(9): 2698. DOI: 10.3390/jcm9092698.
[8]	ZHANG M, ZHANG LR, LUO L, et al. Influence of fatty liver on the severity of acute pancreatitis[J]. J Clin Hepatol, 2022, 38(7): 1595-1601. DOI: 10.3969/j.issn.1001-5256.2022.07.025. 张苗, 张利荣, 罗琳, 等. 合并脂肪肝对急性胰腺炎严重程度的影响[J]. 临床肝胆病杂志, 2022, 38(7): 1595-1601. DOI: 10.3969/j.issn.1001-5256.2022.07.025.
[9]	Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for diagnosis and treatment of acute pancreatitis in China (2021)[J]. Chin J Surg, 2021, 59(7): 578-587. DOI: 10.3760/cma.j.cn112139-20210416-00172. 中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 中华外科杂志, 2021, 59(7): 578-587. DOI: 10.3760/cma.j.cn112139-20210416-00172.
[10]	SUREKA B, BANSAL K, PATIDAR Y, et al. Imaging lexicon for acute pancreatitis: 2012 Atlanta Classification revisited[J]. Gastroenterol Rep (Oxf), 2016, 4(1): 16-23. DOI: 10.1093/gastro/gov036.
[11]	ZENG MD, FAN JG, LU LG, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases[J]. J Dig Dis, 2008, 9(2): 108-112. DOI: 10.1111/j.1751-2980.2008.00331.x.
[12]	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Ⅲ)[J]. JAMA, 2001, 285(19): 2486-2497. DOI: 10.1001/jama.285.19.2486.
[13]	SU L, LI Y. Antimicrobial therapy in patients with acute pancreatitis complicated with infection[J]. J Med Postgra, 2017, 30(7): 684-692. DOI: 10.16571/j.cnki.1008-8199.2017.07.003. 苏磊, 李悦. 急性胰腺炎合并感染的抗生素应用[J]. 医学研究生学报, 2017, 30(7): 684-692. DOI: 10.16571/j.cnki.1008-8199.2017.07.003.
[14]	WU D, SONG LL, ZHAO YH. Study on the relationship between fatty liver and classification of acute pancreatitis[J]. Chin J Lab Diag, 2018, 22(9): 1557-1559. DOI: 10.3969/j.issn.1007-4287.2018.09.023. 吴迪, 宋玲玲, 赵艳辉. 脂肪肝与急性胰腺炎分级的关系研究[J]. 中国实验诊断学, 2018, 22(9): 1557-1559. DOI: 10.3969/j.issn.1007-4287.2018.09.023.
[15]	HOU S, TANG X, CUI H, et al. Fatty liver disease is associated with the severity of acute pancreatitis: A systematic review and meta-analysis[J]. Int J Surg, 2019, 65: 147-153. DOI: 10.1016/j.ijsu.2019.04.003.
[16]	LI J, TIAN T, HU WW, et al. Concomitant nonalcoholic fatty liver disease affects the severity and clinical outcome of acute pancreatitis[J]. Chin J Clinicians, 2021, 49(4): 456-459. DOI: 10.3969/j.issn.2095-8552.2021.04.024. 李吉, 田甜, 胡文炜, 等. 合并非酒精性脂肪性肝病影响急性胰腺炎严重程度和临床结局[J]. 中国临床医生杂志, 2021, 49(4): 456-459. DOI: 10.3969/j.issn.2095-8552.2021.04.024.
[17]	YAN YF, JIANG X, ZHONG R, et al. Clinical features and prognosis of acute pancreatitis with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(5): 1091-1096. DOI: 10.3969/j.issn.1001-5256.2020.05.028. 严永峰, 蒋鑫, 钟瑞, 等. 急性胰腺炎合并非酒精性脂肪性肝病的临床特征及预后分析[J]. 临床肝胆病杂志, 2020, 36(5): 1091-1096. DOI: 10.3969/j.issn.1001-5256.2020.05.028.
[18]	FISIC E, POROPAT G, BILIC-ZULLE L, et al. The role of IL-6, 8, and 10, sTNFr, CRP, and pancreatic elastase in the prediction of systemic complications in patients with acute pancreatitis[J]. Gastroenterol Res Pract, 2013, 2013: 282645. DOI: 10.1155/2013/282645.
[19]	ZHANG M, ZHANG LR, LUO L, et al. Analysis of influence factors of serum CRP level in early onset of acute pancreatitis[J]. J Baotou Med Coll, 2021, 37(10): 71-76. DOI: 10.16833/j.cnki.jbmc.2021.10.017. 张苗, 张利荣, 罗琳, 等. 急性胰腺炎发病早期血清C-反应蛋白水平影响因素分析[J]. 包头医学院学报, 2021, 37(10): 71-76. DOI: 10.16833/j.cnki.jbmc.2021.10.017.
[20]	LI X, KE L, DONG J, et al. Significantly different clinical features between hypertriglyceridemia and biliary acute pancreatitis: a retrospective study of 730 patients from a tertiary center[J]. BMC Gastroenterol, 2018, 18(1): 89. DOI: 10.1186/s12876-018-0821-z.
[21]	SZATMARY P, GRAMMATIKOPOULOS T, CAI W, et al. Acute pancreatitis: diagnosis and treatment[J]. Drugs, 2022, 82(12): 1251-1276. DOI: 10.1007/s40265-022-01766-4.
[22]	PÁRNICZKY A, LANTOS T, TÓTH EM, et al. Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations[J]. Pancreatology, 2019, 19(4): 488-499. DOI: 10.1016/j.pan.2019.04.003.
[23]	LUO YY, LIU X. Research progress of probiotics in adjuvant treatment of severe acute pancreatitis[J]. Trauma Crit Care Med, 2021, 9(2): 161-164. DOI: 10.16048/j.issn.2095-5561.2021.02.22. 罗娅媛, 刘旭. 益生菌辅助治疗重症急性胰腺炎研究进展[J]. 创伤与急危重病医学, 2021, 9(2): 161-164. DOI: 10.16048/j.issn.2095-5561.2021.02.22.
[24]	MORAN RA, HALLORAN C, GUO Q, et al. Early infection is an independent risk factor for increased mortality in patients with culture-confirmed infected pancreatic necrosis[J]. Pancreatology, 2022, 22(1): 67-73. DOI: 10.1016/j.pan.2021.11.003.
[25]	Professional Committee of Pancreatic Disease, Chinese Medical Doctor Association. Chinese consensus on the multidisciplinary treatment (MDT) of acute pancreatitis[J]. J Clin Hepatol, 2015, 31(11): 1770-1775. DOI: 10.3969/j.issn.1001-5256.2015.11.003. 中国医师协会胰腺病学专业委员会. 中国急性胰腺炎多学科诊治共识意见[J]. 临床肝胆病杂志, 2015, 31(11): 1770-1775. DOI: 10.3969/j.issn.1001-5256.2015.11.003.

Relative Articles

[1]	Xueyun GUO, Xuan ZHONG, Tingting ZHANG, Sihai CHEN, Wang ZHANG, Bimin LI, Xuan ZHU, Anjiang WANG. Risk factors for death within 30 days after admission in patients with decompensated liver cirrhosis and acute kidney injury and construction of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(11): 2221-2228. doi: 10.12449/JCH241115
[2]	Naifan PAN, Xuesong SONG. Association between preoperative N-terminal pro-brain natriuretic peptide and acute kidney injury after liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(8): 1653-1660. doi: 10.12449/JCH240823
[3]	Jiaxuan HU, Tao HAN. An excerpt of Asian Pacific Association for the Study of the Liver clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1575-1578. doi: 10.12449/JCH240811
[4]	Yuan WEN, Juanjuan ZHU. Clinical efficacy of double plasma molecular absorption system and sequential plasma exchange combined with continuous renal replacement therapy in treatment of acute-on-chronic liver failure with acute kidney injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 556-561. doi: 10.12449/JCH240319
[5]	Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
[6]	Gerui ZHU, Yani PI, Jing WANG, Kai HUANG, Yuan PENG, Gaofeng CHEN, Chenghai LIU, Yanyan TAO. Efficacy of Astragali Radix extract in treatment of a mouse model of aristolochic acid Ⅰ-induced liver and renal injury by regulating the IL-6/STAT3 signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(8): 1903-1910. doi: 10.3969/j.issn.1001-5256.2023.08.020
[7]	Peng WANG, Zeyu LI, Yating JIANG, Cheng SHANG, Hong WANG. Value of Model for End-Stage Liver Disease score and albumin-bilirubin score combined with β2-microglobulin in predicting liver cirrhosis with acute kidney injury[J]. Journal of Clinical Hepatology, 2023, 39(12): 2839-2844. doi: 10.3969/j.issn.1001-5256.2023.12.014
[8]	Mengyue SHANG, Yalin TONG, Yongzhong CHEN, Jie BAO. Influencing factors for acute kidney injury in acute liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2023, 39(2): 359-364. doi: 10.3969/j.issn.1001-5256.2023.02.016
[9]	Yan WANG, Mingzheng LI, Yufeng LIU, Shiming WANG. Early predictors for acute kidney injury in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1192-1197. doi: 10.3969/j.issn.1001-5256.2022.05.046
[10]	Yuanyuan JIN, Binghua ZHU, Xuejie FEI, Qian WANG. Clinical application of regional citrate anticoagulation in continuous renal replacement therapy for patients with liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 200-203. doi: 10.3969/j.issn.1001-5256.2021.01.044
[11]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[12]	CHEN YuQing, JIANG Xin, XU Huan, ZHONG Rui, LI PeiLing, ZHANG Lu, PENG Yan, TANG XiaoWei. Value of serum cystatin C in predicting acute kidney injury in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2505-2508. doi: 10.3969/j.issn.1001-5256.2020.11.021
[13]	CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006
[14]	Li Ming, Chen RuLi, Wu ZhenPing, Cheng XiaoYu, Mei Qing, Zhang LunLi, Li XiaoPeng. Value of combined measurement of urinary insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2 in predicting acute kidney injury associated with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1560-1564. doi: 10.3969/j.issn.1001-5256.2019.07.027
[15]	Yao YunHai, Gan JianHe, Zhao WeiFeng. Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury[J]. Journal of Clinical Hepatology, 2019, 35(5): 1065-1069. doi: 10.3969/j.issn.1001-5256.2019.05.026
[16]	Lei Lei, Li LiangPing, Zhang Hu. Value of combined measurement of serum cystatin C and urinary neutrophil gelatinase-associated lipocalin in diagnosis of acute kidney injury secondary to cirrhotic ascites[J]. Journal of Clinical Hepatology, 2018, 34(1): 101-105. doi: 10.3969/j.issn.1001-5256.2018.01.021
[17]	Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
[18]	Wan ZhiHong, Wang JianJun, Xie GuoMing, You ShaoLi, Liu HongLing, Zhu Bing, Zang Hong, Xin ShaoJie. Significance of serum cystatin C level for early diagnosis of acute kidney injury in patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2014, 30(7): 666-669. doi: 10.3969/j.issn.1001-5256.2014.07.024
[19]	Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	朱宏坤，戴芳芳，钱世宁. 血必净注射液对行连续性肾脏替代疗法的多器官功能障碍综合征患者凝血功能的影响. 哈尔滨医科大学学报. 2024(01): 75-79 .
2.	肖晶晶. 局部枸橼酸抗凝联合CRRT治疗脓毒症合并急性肾衰竭的临床疗效及对患者凝血功能的影响. 延边大学医学学报. 2024(05): 534-537 .
3.	王娟，张丽萍，丁童，卫淑润，翁志华. 局部枸橼酸抗凝血液净化技术在ICU造血干细胞移植后弥漫性肺泡出血患者治疗中应用价值. 临床军医杂志. 2023(05): 522-524 .
4.	孙卫和，许伟伟，冒秀宏，汪涛. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用. 中外医疗. 2023(18): 129-132 .
5.	赵志强，孟鹏飞，石正松，陈亚君，肖宏涛. 枸橼酸抗凝在脓毒症伴高危出血行连续性肾脏替代治疗患者中的应用效果. 医药论坛杂志. 2023(19): 14-18 .
6.	李一青，白银果，沙莎. 连续性静脉-静脉血液滤过透析和局部枸橼酸抗凝在重症患者乳酸升高时应用的有效性和安全性研究. 贵州医药. 2023(11): 1704-1705 .
7.	张妍，荣阳，张芳. CRRT治疗肾衰竭合并顽固性心力衰竭的临床效果. 中西医结合心脑血管病杂志. 2022(02): 285-288 .
8.	张竞葳，田敏，余建斌. 局部枸橼酸抗凝应用于维持性血液透析合并消化道出血患者的疗效观察. 现代医学与健康研究电子杂志. 2022(13): 130-134 .
9.	陈伟玲，邓虹，黄颖妍，李乐，张洪举. 局部枸橼酸抗凝在连续性肾替代疗法治疗中的效果及安全性指标的变化. 北方药学. 2022(05): 116-119 .
10.	吴允东，江海娇，张伟，曹迎亚，杨尚志，周伟. 不同抗凝方案用于心脏术后患者连续性肾脏替代治疗中的效果. 皖南医学院学报. 2022(05): 436-439+443 .
11.	严海燕，黄雪敏，李大亮，岑树坤，蒋林青. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析. 实用中西医结合临床. 2022(17): 31-33+37 .
12.	金源源，诸炳骅，费雪洁，王倩. 局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用. 临床肝胆病杂志. 2021(01): 200-203 . 本站查看
13.	胡新，毛智，周飞虎. 枸橼酸抗凝在重症患者连续血液净化中的应用进展. 武警医学. 2021(01): 78-81 .
14.	杨向莎，杨福燕，张瑞霞，张军. 改良式枸橼酸钠与低分子量肝素在急性肾损伤CRRT中的抗凝效果比较. 临床医学研究与实践. 2021(20): 46-49 .
15.	冉梦晓，陈辉，郑浩天. 枸橼酸局部抗凝技术在血液透析中的应用进展. 中国医药. 2021(07): 1113-1116 .
16.	杨妮娜，李之诉，杨禄，陈王峰. RCA-CRRT治疗中滤器后离子钙与体内离子钙的相关性. 现代实用医学. 2021(08): 993-995 .
17.	焦清海，郑丽环，张雪梅，王征，杜菲，陈亮. 局部枸橼酸抗凝在危重症患者持续肾脏替代疗法中的临床应用. 河北医科大学学报. 2021(10): 1144-1148 .
18.	王敬文. 枸橼酸与肝素抗凝对重症血液净化患者临床指标和安全性的影响比较. 中外医学研究. 2021(32): 40-43 .
19.	冯菁，李和文，张兴凯，王建华，张作鹏，郭燕蓉，任航奇. 肝衰竭患者行局部枸橼酸抗凝连续性肾脏替代治疗时发生枸橼酸蓄积的影响因素分析. 临床和实验医学杂志. 2021(22): 2402-2406 .
20.	李杨，由丽丽. 连续性肾脏替代治疗脑出血合并急性肾损伤患者中应用局部枸橼酸抗凝治疗的有效性及安全性. 中国医药指南. 2020(36): 89-90 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (388) PDF downloads(26)

Influencing factors for dynamic changes in the severity of fatty liver in patients with acute pancreatitis and fatty liver

DOI: 10.3969/j.issn.1001-5256.2023.06.018